More on AstraZeneca (AZN +1.2% in London) Q3: Pretax profits $2B vs $4.2B, with performance hurt...

|About: AstraZeneca Group plc (AZN)|By:, SA News Editor

More on AstraZeneca (AZN +1.2% in London) Q3: Pretax profits $2B vs $4.2B, with performance hurt by patent expiries. Sales breakdown: Seroquel IR (Schizophrenia) -83% at constant exchange rates to $169M, Nexium (ulcers) -6% to $995M, Arimidex (cancer) -22% to $130M, Crestor (cholesterol) -3% to $1.54B. Reiterates FY EPS forecast of $6-$6.30 vs $7.28 in 2011.